VANCOUVER, British Columbia–(BUSINESS WIRE)–KITS, Canada’s fastest growing eyewear brand is today launching its revolutionary platform KITS.com. Led by a team of industry veterans, KITS is backed by over 70 years of combined experience culminating in…
Author: Business Wire
Global Soft Contact Lens Market (2020 to 2024) – Featuring Menicon, Novartis & SEED Among Others – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Soft Contact Lens Market 2020-2024” report has been added to ResearchAndMarkets.com’s offering. The soft contact lens market is poised to grow by $ 1.71 bn during 2020-2024 progressing at a CAGR of 3% during the for…
Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
VICTORIA, British Columbia–(BUSINESS WIRE)–AURINIA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS
Stanton Optical and My Eyelab’s Affiliated Network of Doctors Providing Free Eye Exams for Kids in August
PALM SPRINGS, Fla.–(BUSINESS WIRE)–Stanton Optical and My Eyelab, leading retail brands of Now Optics offering accessible and affordable eye care and eyewear, and their affiliated network of doctors, are kicking off National Eye Exam Month and back t…
Insights on the Global Ophthalmology PACS Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio
LONDON–(BUSINESS WIRE)– #GlobalOphthalmologyPACSMarket–The Global Ophthalmology PACS Market will grow by USD 59.9 mn during 2020-2024
Eyenuk、糖尿病網膜症スクリーニング用のEyeArt自律的AIシステムに対するFDA認可の取得を発表
ロサンゼルス–(BUSINESS WIRE)–（ビジネスワイヤ） — 人工知能（AI）医療技術・サービスの世界的企業で、AIアイ・スクリーニング向け実臨床アプリケーションのリーダー企業のEyenuk, Inc.は本日、米国の成人における失明の主因となっている糖尿病網膜症に対する自律的AIシステムEyeArt®の上市につき、米国食品医薬品局（FDA）より510(k)認可（K200667）を取得したと発表しました。 EyeArtは、医療提供者が使用して、過去に軽度以上の糖尿病網膜症の診断を受けてい…
Eyenuk宣布FDA核准EyeArt自主AI系統用於糖尿病視網膜病變篩查
洛杉磯–(BUSINESS WIRE)–(美國商業資訊)–Eyenuk, Inc.是一家全球性人工智慧(AI)醫療技術和服務公司，是AI眼病篩檢真實世界應用的領導者，公司今天宣布，美國食品藥品管理局(FDA)已簽發該公司用於糖尿病視網膜病變的EyeArt®自主AI系統上市的510(k)核准(K200667)，該病變是美國成人失明的主要病因。 EyeArt適用於醫療保健提供者，對既往未診斷的輕度以上糖尿病視網膜病變成人眼的輕度以上糖尿病視網膜病變(mtmDR)和威脅視力的糖尿病視網膜病變(vtD…
Eyenuk宣布FDA核准EyeArt自主AI系统用于糖尿病视网膜病变筛查
洛杉矶–(BUSINESS WIRE)–(美国商业资讯)–Eyenuk, Inc.是一家全球性人工智能(AI)医疗技术和服务公司，是AI眼病筛查真实世界应用的领导者，公司今天宣布，美国食品药品管理局(FDA)已签发该公司用于糖尿病视网膜病变的EyeArt®自主AI系统上市的510(k)核准(K200667)，该病变是美国成人失明的主要病因。 EyeArt适用于医疗保健提供者，对既往未诊断的轻度以上糖尿病视网膜病变成人眼的轻度以上糖尿病视网膜病变(mtmDR)和威胁视力的糖尿病视网膜病变(vtD…
COVID-19 Impacts: Glaucoma Surgery Devices Market Will Accelerate at a CAGR of almost 31% through 2020-2024 | Increasing Prevalence of Glaucoma to Boost Growth | Technavio
LONDON–(BUSINESS WIRE)– #GlaucomaSurgeryDevicesMarket–The Global Glaucoma Surgery Devices Market will grow by USD 1.53 bn during 2020-2024
Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Ophthalmic Lens Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Increasing Prevalence of Refractive Errors to boost the Market Growth | Technavio
LONDON–(BUSINESS WIRE)– #GlobalOphthalmicLensMarket–The Global Ophthalmic Lens Market will grow by USD 3.21 bn during 2020-2024
Eyenuk kündigt FDA-Zulassung für das autonome KI-System EyeArt zum Screening auf diabetische Retinopathie an
LOS ANGELES–(BUSINESS WIRE)–Eyenuk, Inc., ein weltweit tätiges Medizintechnik- und -dienstleistungsunternehmen auf dem Gebiet der künstlichen Intelligenz (KI) und führend im Bereich der praktischen Anwendungen für das Augen-Screening, gab heute bekan…
Eyenuk annonce l'autorisation de la FDA pour le système autonome EyeArt pour le dépistage de la rétinopathie diabétique
LOS ANGELES–(BUSINESS WIRE)–Eyenuk, Inc., une société mondiale de technologie et de services médicaux basés sur l’intelligence artificielle (IA) et le leader des applications en situation réelle pour le dépistage des troubles de la vue basé sur l’IA,…
Glaukos Corporation Announces Second Quarter 2020 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced finan…
NovaBay Pharmaceuticals Reports Second Quarter 2020 Financial Results
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay reports second quarter 2020 financial results.
Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Samenvatting: Eyenuk kondigt FDA-goedkeuring aan voor het autonome AI-systeem EyeArt voor screening op diabetische retinopathie
LOS ANGELES–(BUSINESS WIRE)–Eyenuk, Inc., een wereldwijd bedrijf voor kunstmatige intelligentie (AI) op het gebied van medische technologie en services en marktleider in real-world toepassingen voor AI Eye Screening, heeft vandaag aangekondigd dat he…
Eyenuk anuncia la autorización de la FDA del sistema de IA autónoma EyeArt para el examen de la retinopatía diabética
LOS ÁNGELES–(BUSINESS WIRE)–Eyenuk, Inc., una empresa global de tecnología y servicios médicos por inteligencia artificial (IA) y líder en aplicaciones del mundo real de exámenes oculares por IA, anunció hoy que recibió la autorización 510(k) (K20066…
Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseas…
Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for t…